China opens up its pharmaceutical market to its rather hostile neighbor, India while Beijing and Washington have a tiff over President Donald Trump’s renewed warning of added tariffs on Chinese imports worth $200 billion.
After months of inspections, Indian Ministry of Health and Family Welfare have taken a decision to ban the import of Oxytocin in India from 1 July 2018. The government has restricted private manufactures to produce Oxytocin formulations for domestic use, only state-owned Karnataka Antibiotics & Pharmaceuticals Ltd. (KAPL) have been allowed to manufacture and directly supply to registered hospitals and clinics across India.
Last Friday, pharma giant AstraZeneca announced that it had received the go-ahead from the Drug Controller General of India (DCGI) to import and market durvalumab (ImfinziTM) in India. The receipt of this permission paves the way for the launch of durvalumab (ImfinziTM) in India. Durvalumab which is a patented drug of Astra-Zeneca, received permission in India to provide treatment for patients with unresectable non-small cell lung cancer and metastatic urothelial carcinoma.
Key findings of the FHI 2018 allude to the lack of access on account of low skilled physician density and a low number of hospital beds. The study also highlighted the fact that semi-urban and rural areas are yet to leverage the advancements of digital healthcare. It also stated that healthcare professionals in the country were open to the deployment of futuristic technology such as AI and virtual reality in healthcare as compared to the general population.
On Sunday, the World Health Organization praise India's progress in reducing the maternal mortality ratio (MMR) by 77%. According to their statistics rates have dropped from 556 per 1,00,000 live births in 1990 to 130 per 1,00,000 live births in 2016. As a result of achieving this milestone, hopes are high for India to be on track towards reaching their Sustainable Development Goal (SDG) target of an MMR below 70 by 2030.
Niti Aayog is focusing on proposals to encourage domestic manufacturing of medical devices following orders from the Prime Minister's Office, said the expert. The meeting was focused on identifying the problems in local manufacturing and quality of the devices produced in India and also to spot the solution for the issues.
Determined to cap the profits of private hospitals in Delhi and the NCR region, Delhi health minister Satyendra Jain has announced an array of new rules. He clearly stated that hospitals will be mandated to sell essential medicines at MRP and can no longer charge a markup.
India-based Omega Healthcare has categorically stated that the growth of data analytics and cloud intelligence firms in the Indian healthcare sector has little scope. The company plans to hire around 1,200 - 1,500 people for exploring emerging markets like the United Arab Emirates.
The IVD sector in the country is chiefly characterized by 70 percent laboratories offering pathology services and 30 percent entities doling out radiology and imaging services. Though domestic players are flexing their muscles and are gearing to provide new-age diagnostic services with path-breaking innovations and strategic investments, multinational companies continue to hold sway over 60% of the domestic IVD market which is expected to grow by leaps and bounds in coming times.
NiV was first discovered in Malaysia and Singapore in 1998-1999 where around 250 infected cases and 100 deaths were reported. Between 2001 and 2004, NiV caused a deadly outbreak in Bangladesh followed by the West Bengal state in India.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.